Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

ly, ARIUS has antibody programs targeting the MCSP antigen and

37LRP, in addition to several other undisclosed programs.

- ARIUS now has 26 issued or allowed patents covering its antibody

programs and discovery platform and over 273 patents pending

worldwide.

Corporate Updates

- Dr. Young was awarded "Most Innovative" award by the Association of

Chinese Canadian Entrepreneurs for demonstration of exceptional

innovation in his field and contribution to the marketplace.

- Secured a sponsored research agreement with the University of Toronto

Health Network and cancer stem cell pioneer, Dr. John E. Dick. In

collaboration with Dr. Dick, ARIUS is assessing the impact of certain

antibodies on cancer stem cells.

- Continued to evaluate its strategic options with global

pharmaceutical and biotechnology companies.

Financial Results:

All amounts are in Canadian dollars unless otherwise indicated.

For the six-month period ended May 31, 2008, the Company recorded a net loss of $6,401,018 ($0.14 per share) compared to a net loss of $5,342,827 ($0.12 per share) for the six-month period ended May 31, 2007. For the three-month period ended May 31, 2008, the Company recorded a net loss of $3,816,937 ($0.08 per share) compared to a net loss of $3,036,132 ($0.07 per share) for the three-month period ended May 31, 2007. This increase in net loss for both periods is primarily the result of higher research and development, and general administrative expenses, partially offset by higher revenues and foreign exchange gains.

For the six-month period ended May 31, 2008, the Company's revenue increased to $1,471,447 compared to $129,846 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's revenue increased to $424,153 compared to $21,392 for the same period in fiscal 2007. The increase for both pe
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 year anniversary ... one of its latch valves, V27200-818, operating onboard this ... of the planet Mercury. It is only the second ... a vast amount of information and images of the ... solenoids that also include permanent magnets to maintain the ...
(Date:9/16/2014)... jaw movements has been created by a group of ... device can generate electricity from eating, chewing and talking, ... electronic devices, such as hearing aids, cochlear implants, electronic ... of the device,s performance have been published today, 17 ... Structures . , Jaw movements have proved to be ...
(Date:9/16/2014)... BlueInGreen® , a water ... for delivering dissolved gases into liquids, announced the ... a manufacturer’s representative firm to its sales network. ... municipal water and wastewater applications in the Canadian ... founded in 1992 and serves Quebec and Ontario ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
Breaking Biology Technology:'Smart material' chin strap harvests energy from chewing 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
(Date:9/16/2014)... Proteins are responsible for practically all vital functions ... reactions, forward signals, transport particular substances and control ... that proteins do not function independently of each ... you examine the protein networks, you find many ... Falter-Braun from TUM,s Chair of Plant Systems Biology. ...
Breaking Biology News(10 mins):New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
ImageQuant 300, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
Request Info...
Recombinant Feline IL-5...
Biology Products: